Q32 Bio
QTTB
62 hedge funds and large institutions have $20M invested in Q32 Bio in 2023 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 9 increasing their positions, 17 reducing their positions, and 18 closing their positions.
975% more call options, than puts
Call options by funds: $43K | Put options by funds: $4K
0.23% less ownership
Funds ownership: 2.1% → 1.87% (-0.23%)
22% less funds holding
Funds holding: 79 → 62 (-17)
26% less capital invested
Capital invested by funds: $27.1M → $20M (-$7.13M)
47% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 17
83% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$194K |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$176K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$85.8K |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$24.5K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$15K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$2.04M |
| 2 |
OMC
Oasis Management Company
Grand Cayman,
Cayman Islands
|
-$353K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$287K |
| 4 |
BlackRock
New York
|
-$144K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$82K |
QTTB Hedge Fund Activity: Q1 2023 in Review
62 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Q32 Bio (QTTB) for Q1 2023, worth a combined $20M — down 26% from $27.1M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of QTTB and 3 opened new positions — a net loss of 15 holders — while 17 trimmed existing stakes and 9 added.
The largest buyer was Morgan Stanley, adding an estimated $194K. The largest seller was Bellevue Group, exiting entirely with an estimated $2.04M sold.
- 62 institutional investors held Q32 Bio (QTTB) as of Q1 2023, down from 79 in Q4 2022.
- Funds reported $20M of Q32 Bio stock for Q1 2023, down 26% quarter-over-quarter.
- 3 funds opened new Q32 Bio positions in Q1 2023 and 18 closed out, a net change of -15 holders.
- The largest Q32 Bio buyer in Q1 2023 was Morgan Stanley, an estimated $194K added.
- The largest Q32 Bio seller in Q1 2023 was Bellevue Group, an estimated $2.04M sold.
Based on aggregated 13F filings for Q1 2023.